Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834665 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00834665: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT00834665 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834665, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is: 1. To evaluate the safety of activated T cell infusions and immunization with hTERT multi-peptide vaccine in the post-transplant setting and whether the combination can delay hematopoietic recovery or induce other autoimmune events. 2. To determine whether the strategy of infusing vaccine-primed T-cells early after transplant in conjunction with post-transplant boosters leads to the induction of cellular immune responses to hTERT.
Interventions
- BIOLOGICAL hTERT vaccine, GM-CSF, PCV, T cell infusion
- BIOLOGICAL GM-CSF, PCV, T cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-12 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834665
The ClinicalTrials.gov registry entry for NCT00834665 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hTERT vaccine, GM-CSF, PCV, T cell infusion is the first listed.
NCT00834665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834665 about?
NCT00834665 is a clinical study titled "Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma". The purpose of this study is: 1. To evaluate the safety of activated T cell infusions and immunization with hTERT multi-peptide vaccine in the post-transplant setting and whether the combination can delay hematopoietic recovery or induce other autoimmune events. 2. To determine whether the strategy...
What is the current status of trial NCT00834665?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2006-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT00834665?
The interventions under investigation include: hTERT vaccine, GM-CSF, PCV, T cell infusion (BIOLOGICAL), GM-CSF, PCV, T cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00834665?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.